OS Therapies reports FY2024 net operating loss of $10.9M; cash runway into 2026

OS Therapies Inc

2025-Q1 EPS reported -$0.18 vs consensus -$0.08 ▼ miss (-120.6%)

Net operating loss $10.886M in 2024 vs $7.916M in 2023, driven by IPO costs.
Net loss per share $0.88 on 12.38M shares vs $1.46 on 5.43M shares in 2023.
Cash on hand expected to last into 2026 due to reduced burn rate starting Q2 2025.
Full Phase 2b OST-HER2 data to be presented June 2025; BLA submission targeted for year-end 2025.
Plans to divest anticipated Priority Review Voucher (PRV) from potential BLA approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.